Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire...

Founded in 2010
Total money raised: $252M

02451 1000 Winter St
Suite #3300


Phone: 339.970.0900

Updated on Feb 22, 2014
TESARO at CrunchBase
David Mott Chairman
Lonnie Moulde Co-Founder, CEO
Mary Lynne Hedley President, CSO and co-founder
Rick Rodgers CFO
Scott Weiner Board Observer
Arnold Oronsky Board of Directors
Larry Alleva Board Member
Sara Nayeem Board Observer

March, 2013

TESARO raised $91M in post_ipo_equity round

Tesaro pockets $91M in big financing as major cancer trials continue

July, 2012

Stock symbol: NASDAQ:TSRO

March, 2012

Tesaro seeks $86.2M IPO

June, 2011

TESARO raised $101M in a Series B round from Kleiner Perkins Caufield & Byers, New Enterprise Associates, InterWest Partners, T. Rowe Price, and Pappas Ventures

TESARO Secures $101M in Series B Financing

March, 2011

landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen’s Anaplastic Lymphoma Kinase (ALK) technology

Tesaro buys rights to Amgen lung cancer tech program

December, 2010

has signed a deal with Miami-based OPKO Health Inc. that will bring the Boston firm exclusive rights to develop, manufacture, commercialize and distribute rolapitant, a cancer-related treatment

Biotech startup Tesaro lands licensing deal for cancer treatment

May, 2010

TESARO raised $60M in a Series A round from New Enterprise Associates

Tesaro, Inc.: Series A $60M

March, 2010

TESARO was founded on March, 2010